Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies

Atherosclerosis

Volumn 244, Issue , 2016, Pages 44-47

  Wallukat, Gerd ^a   Müller, Johannes ^a   Haberland, Annekathrin ^a   Berg, Sabine ^b   Schulz, Angela ^c   Freyse, Ernst Joachim ^b   Vetter, Roland ^c   Salzsieder, Eckhard ^b   Kreutz, Reinhold ^c   Schimke, Ingolf ^a  

^a Berlin Space Technologies GmbH   (Germany)

^b Institut fur Diabetes 'Gerhardt Katsch'   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aptamer; Autoantibodies; Beta1 adrenergic receptor; Cardiomyopathy; G protein coupled receptor

Indexed keywords

APTAMER; AUTOANTIBODY; G PROTEIN COUPLED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; EX VIVO STUDY; HUMAN; IMMUNOADSORPTION; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; APHERESIS; CARDIAC MUSCLE CELL; CARDIOMYOPATHIES; CELL CULTURE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; NEWBORN; PATHOLOGY; PROCEDURES; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANIMALS, NEWBORN; APTAMERS, NUCLEOTIDE; AUTOANTIBODIES; BLOOD COMPONENT REMOVAL; CARDIOMYOPATHIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; MYOCYTES, CARDIAC; RATS; RATS, INBRED SHR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84946867351     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.11.001     Document Type: Article

References (22)

1. Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin. Immunopathol. 2014, 36:351-363.
2. Wallukat G., Wollenberger A. Effects of gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed. Biochim. Acta 1987, 46:S634-S639.
3. Fu M.L. Anti-M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy. Int J Cardiol. 1996, 54:127-135.
4. Wallukat G., Munoz-Saravia S.G., Haberland A., Bartel S., Araujo R., Valda G., Duchen D., Ramirez I.D., Borges A.C., Schimke I. Distinct pattern of autoantibodies against G-protein coupled receptors in Chagas' cardiomyopathy and megacolon. J. Am. Coll. Cardiol. 2010, 55:463-468.
5. Liu J., Wang Y., Chen M., Zhao W., Wang X., Wang H., Zhang Z., Zhang J., Xu L., Chen J., Yang X., Zhang L. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One 2014 Jan 23, 9(1):e86770.
6. Hempel P., Karczewski P., Kohnert K.D., Raabe J., Lemke B., Kunze R., Bimmler M. Sera of patients with type2 diabetes contain agonistic autoantibodies against G-protein coupled receptors. Scand. J. Immunol. 2009, 70:159-160.
7. Luther H.P., Homuth V., Wallukat G. Alpha1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 1997, 29:678-682.
8. Dandel M., Wallukat G., Englert A., Lehmkul H.B., Hetzer R. Potential pathogenetic involvement of agonistic autoantibodies against alpha-1 adrenergic and endothelin-1 receptors in pulmonary arterial hypertension. Circulation 2008, 118:S1072.
9. Dandel M., Wallukat G., Englert V, Lehmkuhl H.B., Knosalla C., Hetzer R. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur. J. Heart Fail. 2012, 14:1374-1388.
10. Dandel M., Englert V., Wallukat G., Riese A., Knosalla C., Stein J., Hetzer R. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus. Atheroscler. Suppl. 2015, 18:124-133.
11. Haberland A., Wallukat G., Schimke I. Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment. Trends Cardiovasc Med. 2011, 21:177-182.
12. Haberland A., Wallukat G., Berg S., Schulz A.M., Freyse E.J., Vetter R., Salzsieder E., Müller J., Kreutz R., Schimke I. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Mol. Cell Biochem. 2014, 393:177-180.
13. Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9:537-650.
14. Marquis J.K., Grindel J.M. Toxicological evaluation of oligonucleotide therapeutics. Curr. Opin. Mol. Ther. 2000, 2:258-263.
15. Schimke I, Haberland A, Wallukat G. Use of aptamers in therapy and/or diagnosis of autoimmune diseases. EP 2012/2497828A1, WO 2012/2012119938A2.
16. Haberland A., Wallukat G., Dahmen C., Kage A., Schimke I. Aptamer neutralization of beta1-adrenoceptror autoantibodies isolated from patients with cardiomyopathies. Circ. Res. 2011, 109:986-992.
17. Wallukat G., Müller J., Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N. Engl. J. Med. 2002, 347:1806.
18. Schimke I., Müller J., Dandel M., Gremmels H.D., Bayer W., Wallukat B., Wallukat G., Hetzer R. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J. Clin. Apher. 2005, 20(3):137-142.
19. Jahns R, Jahns V, Lohse M, Palm D. Means for the inhibition of anti-1-adrenergic receptor antibodies. WO 2006/103101 A2.
20. Dandel M., Wallukat G., Englert A., Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler. Suppl. 2013, 14:203-211.
21. Karczewski P., Hempel P., Kunze R., Bimmler M. Agonistic autoantibodies to the α1-adrenergic and the β2-adrenergic receptor in Alzheimer's and vascular dementia. Scand. J. Immunol. 2012, 75:524-530.
22. Karczewski P., Pohlmann A., Wagenhaus B., Wisbrun N., Hempel P., Lemke B., Kunze R., Niendorf T., Bimmler M. Antibodies to the α1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One 2012, 7(7):e41602.